CD274 and neoplasm: PD-1/PD-L1 expression in tumour cells and in the tumour microenvironment, genetic alterations, mutational load in tumour cells, epigenetic changes, miRNAs expression, pre-existing immunity and its enhancement during treatment by the tumour-infiltrating immune cells were associated with better outcomes and were shown to be predictors for immune checkpoint inhibition.